Transaction DateRecipientSharesTypePriceValue
27th January 2020Linda F Powers220,000Open or private sale$4.60$1,012,000.00
11th September 2019Mark William Lowdell2,918Open or private purchase$6.23$18,178.56
21st August 2019Scott Juda2,500Open or private purchase$6.00$15,000.00
20th August 2019Raymond Joseph Tesi100Open or private purchase$5.96$596.00
20th August 2019Raymond Joseph Tesi100Open or private purchase$5.96$596.00
20th August 2019Raymond Joseph Tesi100Open or private purchase$5.96$596.00
20th August 2019Raymond Joseph Tesi100Open or private purchase$5.96$596.00
20th August 2019Raymond Joseph Tesi100Open or private purchase$5.96$596.00
20th August 2019Raymond Joseph Tesi100Open or private purchase$5.96$596.00
20th August 2019Scott Juda2,500Open or private purchase$6.00$15,000.00
I Nmune Bio
I Nmune Bio logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Inmune Bio, Inc. develops immunotherapies that reprogram a patient's innate immune system to fight cancer. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.


Ticker: INMB
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1711754
Employees: 4
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals